Clinical Trial Update: Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial results for a three-drug combination of fulvestrant, palbociclib, and erdafitinib in ER+/HER2-/FGFR-amplified metastatic breast cancer have been p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BALVERSA (erdafitinib)
• Faslodex (fulvestrant)
• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Metastatic Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2023-02-16